Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells

Curative responses in the treatment of multiple myeloma (MM) are limited by the emergence of therapeutic resistance. To address this problem, we set out to identify druggable mechanisms that convey resistance to proteasome inhibitors (PIs; e.g., bortezomib), which are cornerstone agents in the treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Thompson, Ravyn M., Dytfeld, Dominik, Reyes, Leticia, Robinson, Reeder M., Smith, Brittany, Manevich, Yefim, Jakubowiak, Andrzej, Komarnicki, Mieczyslaw, Przybylowicz-Chalecka, Anna, Szczepaniak, Tomasz, Mitra, Amit K., Van Ness, Brian G., Luczak, Magdalena, Dolloff, Nathan G.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482623/
https://ncbi.nlm.nih.gov/pubmed/28415782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16262
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados